Evidence map›Paper›PMID 32911907›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2020

[Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].

W W Zang, M H Su, X Z Ling, R M Wang, B C Cao, Y L Wu, D L Deng, H L Wei, X S Liang, J N Jiang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. [Risk prediction model of hepatitis B associated hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

W W ZangDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
M H SuDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
X Z LingDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
R M WangDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
B C CaoDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Y L WuDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
D L DengDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
H L WeiDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
X S LiangDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
J N JiangDepartment of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Nantong University · CN

Funding

Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis GXCDCKL201802Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education GKE2018-05, GKE2019-04National Natural Science Foundation 81960115National Science and Technology Major Project of China 2017ZX10202201
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularHepatitis BHepatitis B, ChronicLiver NeoplasmsChinaHepatitis B virusHumansLamivudineLiver CirrhosisRetrospective StudiesRisk FactorsAntiviral AgentsLamivudineHepatitis B, chronicHepatocellular carcinomaLiver cirrhosisNucleoside (acid) analogues

Identifiers

PMID32911907
PMCPMC12854834
OpenAlexW3086483601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.